foxo4-dri senolytic or senomorphic

foxo4-dri senolytic or senomorphic The disordered p53 transactivation domain is the target of FOXO4 and the compound Cleara Biotech senolytic candidate FOXO4-DRI

Name: foxo4-dri senolytic or senomorphic The disordered p53 transactivation domain is the target of FOXO4 and the compound Cleara Biotech senolytic candidate FOXO4-DRI
Brand: metron-ms.com
SKU: 28102934640
Price: 29.36 USD
Availability: InStock
Rating: 4.0117 (24 reviews)

Cleara Biotech senolytic candidate FOXO4 DRI CHK2 USP37 axis stabilizes FOXO4 to sustain senescence and evade apoptosis PNAS Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging PMC Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link

SKU: 28102934640 · From metron-ms.com

4.0

USD29.36 USD61.36

Pay in 4 interest-free payments of $7.34 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 3 - Aug 8

Description

It pairs an N-acetylated Semax backbone with a C-terminal adamantane modification (borrowed from Peptide 021/P21), engineered for enhanced metabolic stability, blood-brain-barrier penetration, and extended duration of BDNF-modulating activity